Singapore, October 5 2020– Vela Diagnostics announced today the release of the ViroKey™ Flu A/B & RSV RT-PCR Extension Kit for research use (RUO). This extension kit is intended for use with Vela Diagnostics’ automated PCR workflow with the ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 which tests for the SARS-CoV-2 virus.
The concurrent use of ViroKey™ Flu A/B & RSV RT-PCR Extension Kit with ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 allows the differentiation of four virus types – Influenza A, Influenza B, Respiratory Syncytial Virus (RSV) and SARS-CoV-2 – in nasopharyngeal and oropharyngeal swabs.
The ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 has garnered Emergency Use Authorization (EUA) from the U.S. FDA, CE-IVD and Australian Therapeutic Goods Administration (TGA) approvals, as well as Provisional Authorisation from the Health Sciences Authority in Singapore.
The automated workflow comprises of the Sentosa™ SX101 instrument and the Sentosa™ SA201 RT-PCR instrument, or the ABI 7500 Fast Dx. This workflow enables minimal hands-on time and tests for up to 46 samples and two controls per run with a turnaround time expected at 4.5 hours.
“The release of our Flu and RSV extension test kit is timely. It is a challenge to differentiate between Flu, RSV and SARS-CoV-2 simply based on symptoms alone, and with the flu season expected in the coming month, this solution will aid in the research of those respiratory viruses,” said Sam Dajani, CEO and Chairman of the Board.
About Vela Diagnostics
Vela Diagnostics is a leading provider for integrated IVD system solutions, from sample to result. VELA’s test solutions utilize the automated Sentosa™ platform, providing the unique ability to leverage one system for NGS and PCR testing in infectious disease and oncology.
All Sentosa™ products listed above are by Vela Diagnostics. For more information, visit www.veladx.com.